Advances in technologies for cervical cancer detection in low-resource settings

Kundrod, Kathryn; Smith, Chelsey; Hunt, Brady; Schwarz, Richard A.; Schmeler, Kathleen M.; Richards‐Kortum, Rebecca

doi:10.1080/14737159.2019.1648213

Cited by 38 publications

(50 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, technical innovations allowing for point-of-care HPV testing exist but remain too costly for widespread use in LMICs. 33 , 34 However, the current WHO Global Strategy for cervical cancer elimination stresses the importance of market incentives to improve access to high performance diagnostics such as HPV tests. 34 …”

Section: Discussionmentioning

confidence: 99%

Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda

Muhimpundu

Ngabo

Sayinzoga

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE To describe the first year results of Rwanda's Screen, Notify, See, and Treat cervical cancer screening program, including challenges encountered and revisions made to improve service delivery. METHODS Through public radio broadcasts, meetings of local leaders, church networks, and local women's groups, public awareness of cervical cancer screening opportunities was increased and community health workers were enlisted to recruit and inform eligible women of the locations and dates on which services would be available. Screening was performed using human papillomavirus (HPV) DNA testing technology, followed by visual inspection with acetic acid (VIA), and cryotherapy, biopsy, and surgical treatment for those who tested HPV-positive. These services were provided by five district hospitals and 15 health centers to HIV-negative women of age 35-45 and HIV-positive women of age 30-50. Service utilization data were collected from the program's initiation in September 2013 to October 2014. RESULTS Of 7,520 cervical samples tested, 874 (11.6%) screened HPV-positive, leading 780 (89%) patients to undergo VIA. Cervical lesions were found in 204 patients (26.2%) during VIA; of these, 151 were treated with cryoablation and 15 were referred for biopsies. Eight patients underwent complete hysterectomy to treat advanced cervical cancer. Challenges to service delivery included recruitment of eligible patients, patient loss to follow-up, maintaining HIV status confidentiality, and efficient use of consumable resources. CONCLUSION Providing cervical cancer screening services through public health facilities is a feasible and valuable component of comprehensive women's health care in resource-limited settings. Special caution is warranted in ensuring proper adherence to follow-up and maintaining patient confidentiality.

show abstract

Section: Discussionmentioning

confidence: 99%

Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda

Muhimpundu

Ngabo

Sayinzoga

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

“…The careHPV test costs $5–42/test, while the GeneXpert costs $20/test. 18 However, the instrumentation cost for the careHPV test is $20,000, while the instrumentation cost for the GeneXpert tests ranges from $11,530 to 71,500. 18 The retail cost of a hand-held potentiostat needed to run our electrochemical tests is $2000 (Palmsens).…”

Section: Introductionmentioning

confidence: 99%

Electrochemical Strategy for Low-Cost Viral Detection

et al. 2021

View full text Add to dashboard Cite

Sexually transmitted infections, including the human immunodeficiency virus (HIV) and the human papillomavirus (HPV), disproportionally impact those in low-resource settings. Early diagnosis is essential for managing HIV. Similarly, HPV causes nearly all cases of cervical cancer, the majority (90%) of which occur in low-resource settings. Importantly, infection with HPV is six times more likely to progress to cervical cancer in women who are HIV-positive. An inexpensive, adaptable point-of-care test for viral infections would make screening for these viruses more accessible to a broader set of the population. Here, we report a novel, cost-effective electrochemical platform using gold leaf electrodes to detect clinically relevant viral loads. We have combined this platform with loop-mediated isothermal amplification and a CRISPR-based recognition assay to detect HPV. Lower limits of detection were demonstrated down to 10 4 total copies of input nucleic acids, which is a clinically relevant viral load for HPV DNA. Further, proof-of-concept experiments with cervical swab samples, extracted using standard extraction protocols, demonstrated that the strategy is extendable to complex human samples. This adaptable technology could be applied to detect any viral infection rapidly and cost-effectively.

show abstract

“…1. 3.4 The mortality rate from cervical cancer remains high in low and middle income countries (LMICs = low-middle income country) due to low human resources, difficulties in implementing and sustaining early detection/routine screening programs, accurate diagnosis, and early treatment of cervical precancerous lesions, poverty, and lack of infrastructure 6,7 . The high incidence of cervical cancer in developing countries is due to the inoperability of a comprehensive populationbased pre-cervical cancer lesion detection system, in addition to low awareness, education and public knowledge about the occurrence of this cancer even though this disease can be prevented and can be cured if the patient comes at the time.…”

Section: Cervical Cancer Epidemiology and Risk Factorsmentioning

confidence: 99%

Epidemiology and Risk Factors for Cervical Cancer

Agustiansyah

Sanif

Nurmaini

et al. 2021

bsm

View full text Add to dashboard Cite

Cervical cancer in Indonesia in 2018 ranks second in cancer in women inIndonesia with an incidence rate of 348.809 cases with a mortality rate of nearly60% of the incidence, namely 207.210 deaths. Deaths from cervical cancer areprojected to continue to increase and are estimated to reach 12 million deaths by2030 if not treated properly. The incidence of cervical cancer in Indonesia isestimated to have 180.000 new cases per year and the death rate is thought toreach 75% in the first year. This death is mainly associated with the majority ofnewly diagnosed patients who are already at an advanced stage (70% of cases) andare already at the terminal stage at the time of diagnosis.

show abstract

Advances in technologies for cervical cancer detection in low-resource settings

Cited by 38 publications

References 117 publications

Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda

Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda

Electrochemical Strategy for Low-Cost Viral Detection

Epidemiology and Risk Factors for Cervical Cancer

Contact Info

Product

Resources

About